New hope for liver transplant patients with recurrent cancer: immunotherapy combo under study
NCT ID NCT06254248
First seen Jan 08, 2026 · Last updated Jun 20, 2026 · Updated 32 times
Summary
This phase 2 trial is testing whether a combination of two drugs, atezolizumab and bevacizumab, can safely treat liver cancer that has come back after a liver transplant. The study includes 50 patients who will receive the drug combo every three weeks along with a strict immunosuppressive regimen to lower the risk of organ rejection. The main goal is to see how many patients experience acute cellular rejection within six months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER TRANSPLANT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU Montpellier - Hôpital Saint Eloi
RECRUITINGMontpellier, 34295, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CHU Rennes - Hôpital Pontchaillou
RECRUITINGRennes, 35033, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CHU Tours - Hôpital Trousseau
RECRUITINGTours, 37044, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hôpital Beaujon
RECRUITINGClichy, 92110, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hôpital Claude Huriez - CHU de Lille
RECRUITINGLille, 59037, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hôpital Henri-Mondor
RECRUITINGCréteil, 94010, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hôpital Paul Brousse
RECRUITINGVillejuif, 94800, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hôpital Pitié-Salpêtrière
RECRUITINGParis, 75013, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hôpital de Hautepierre - Strasbourg
RECRUITINGStrasbourg, 67200, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Lyon - Hôpital Croix Rousse
RECRUITINGLyon, 69004, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Atezolizumab-Bevacizumab (immunotherapy plus anti-angiogenic drug) combined with standard immunosuppressants (tacrolimus, mycophenolate mofetil, corticosteroids, and possibly everolimus)
What this could lead to
If this works, it could offer a new treatment option for liver transplant patients whose cancer has returned, potentially controlling the cancer without causing organ rejection.
What could go wrong
This is a small, early-phase trial with only 50 participants, and the immunotherapy may still trigger liver rejection despite the added immunosuppression. The results may not apply to all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.